Quantum量子訊息有限公司
← 最新全球產業報告

Global Adeno-Associated Virus (AAV) Vector Production CDMO Market

研究執行與發布：Global Info Research　·　發布日期 2026-08-21　·　175 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

出版商 Global Info Research產業別 Healthcare & Life Sciences出版日期 2026-08-21頁數 175報告編號 GIR202601094495

授權報價

Single User License$3,480 USD
Multi User License$5,220 USD
Corporate Users License$6,960 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Global Adeno-Associated Virus (AAV) Vector Production CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

報告摘要

According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Vector Production CDMO market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period. Adeno-Associated Virus (AAV) Vector Production CDMO (Contract Development and Manufacturing Organization) refers to companies that specialize in the development and large-scale production of AAV vectors, which are commonly used as gene therapy delivery systems. CDMOs provide a range of services including vector design, process development, scale-up, manufacturing, and quality control under Good Manufacturing Practices (GMP) standards. These organizations support biotechnology and pharmaceutical companies by producing clinical-grade AAV vectors for preclinical research, clinical trials, and commercial use, helping to meet the growing demand for gene therapies. This report is a detailed and comprehensive analysis for global Adeno-Associated Virus (AAV) Vector Production CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided. Key Features: Global Adeno-Associated Virus (AAV) Vector Production CDMO market size and forecasts, in consumption value ($ Million), 2021-2032 Global Adeno-Associated Virus (AAV) Vector Production CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032 Global Adeno-Associated Virus (AAV) Vector Production CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032 Global Adeno-Associated Virus (AAV) Vector Production CDMO market shares of main players, in revenue ($ Million), 2021-2026 The Primary Objectives in This Report Are: To determine the size of the total market opportunity of global and key countries To assess the growth potential for Adeno-Associated Virus (AAV) Vector Production CDMO To forecast future growth in each product and end-use market To assess competitive factors affecting the marketplace This report profiles key players in the global Adeno-Associated Virus (AAV) Vector Production CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals. Market segmentation Adeno-Associated Virus (AAV) Vector Production CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type Adherent Culture Suspension Culture Market segment by Application Vaccine Development Gene Therapy Academic Scientific Research Institution Others Market segment by players, this report covers Thermo Fisher Scientific Lonza Catalent Charles River Merck SK pharmteco Oxford Biomedica AGC Biologics（MolMed） Gene Universal Polyplus (Sartorius) CCRM FUJIFILM Diosynth Biotechnologies Biovian Miltenyi Bioindustry Aldevron Takara Bio Yposkesi Genezen Exthera GenScript ProBio EurekaBio Obio Technology GeneSail Biotech VectorBuilder WuXi ATU Ubrigene Porton Biologics Pharmaron PackGene Biotechnology Market segment by regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia, Italy and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific) South America (Brazil, Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa) The content of the study subjects, includes a total of 13 chapters: Chapter 1, to describe Adeno-Associated Virus (AAV) Vector Production CDMO product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top players of Adeno-Associated Virus (AAV) Vector Production CDMO, with revenue, gross margin, and global market share of Adeno-Associated Virus (AAV) Vector Production CDMO from 2021 to 2026. Chapter 3, the Adeno-Associated Virus (AAV) Vector Production CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast. Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032. Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Adeno-Associated Virus (AAV) Vector Production CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032. Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis. Chapter 12, the key raw materials and key suppliers, and industry chain of Adeno-Associated Virus (AAV) Vector Production CDMO. Chapter 13, to describe Adeno-Associated Virus (AAV) Vector Production CDMO research findings and conclusion.
目錄 Table of Contents
1 Market Overview 1.1 Product Overview and Scope 1.2 Market Estimation Caveats and Base Year 1.3 Classification of Adeno-Associated Virus (AAV) Vector Production CDMO by Type 1.3.1 Overview: Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type: 2021 Versus 2025 Versus 2032 1.3.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type in 2025 1.3.3 Adherent Culture 1.3.4 Suspension Culture 1.4 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market by Application 1.4.1 Overview: Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application: 2021 Versus 2025 Versus 2032 1.4.2 Vaccine Development 1.4.3 Gene Therapy 1.4.4 Academic Scientific Research Institution 1.4.5 Others 1.5 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size & Forecast 1.6 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast by Region 1.6.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region: 2021 VS 2025 VS 2032 1.6.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region, (2021-2032) 1.6.3 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Prospect (2021-2032) 1.6.4 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Prospect (2021-2032) 1.6.5 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Prospect (2021-2032) 1.6.6 South America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Prospect (2021-2032) 1.6.7 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Prospect (2021-2032) 2 Company Profiles 2.1 Thermo Fisher Scientific 2.1.1 Thermo Fisher Scientific Details 2.1.2 Thermo Fisher Scientific Major Business 2.1.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.1.4 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.1.5 Thermo Fisher Scientific Recent Developments and Future Plans 2.2 Lonza 2.2.1 Lonza Details 2.2.2 Lonza Major Business 2.2.3 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.2.4 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.2.5 Lonza Recent Developments and Future Plans 2.3 Catalent 2.3.1 Catalent Details 2.3.2 Catalent Major Business 2.3.3 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.3.4 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.3.5 Catalent Recent Developments and Future Plans 2.4 Charles River 2.4.1 Charles River Details 2.4.2 Charles River Major Business 2.4.3 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.4.4 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.4.5 Charles River Recent Developments and Future Plans 2.5 Merck 2.5.1 Merck Details 2.5.2 Merck Major Business 2.5.3 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.5.4 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.5.5 Merck Recent Developments and Future Plans 2.6 SK pharmteco 2.6.1 SK pharmteco Details 2.6.2 SK pharmteco Major Business 2.6.3 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.6.4 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.6.5 SK pharmteco Recent Developments and Future Plans 2.7 Oxford Biomedica 2.7.1 Oxford Biomedica Details 2.7.2 Oxford Biomedica Major Business 2.7.3 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.7.4 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.7.5 Oxford Biomedica Recent Developments and Future Plans 2.8 AGC Biologics（MolMed） 2.8.1 AGC Biologics（MolMed） Details 2.8.2 AGC Biologics（MolMed） Major Business 2.8.3 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.8.4 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.8.5 AGC Biologics（MolMed） Recent Developments and Future Plans 2.9 Gene Universal 2.9.1 Gene Universal Details 2.9.2 Gene Universal Major Business 2.9.3 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.9.4 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.9.5 Gene Universal Recent Developments and Future Plans 2.10 Polyplus (Sartorius) 2.10.1 Polyplus (Sartorius) Details 2.10.2 Polyplus (Sartorius) Major Business 2.10.3 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.10.4 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.10.5 Polyplus (Sartorius) Recent Developments and Future Plans 2.11 CCRM 2.11.1 CCRM Details 2.11.2 CCRM Major Business 2.11.3 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.11.4 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.11.5 CCRM Recent Developments and Future Plans 2.12 FUJIFILM Diosynth Biotechnologies 2.12.1 FUJIFILM Diosynth Biotechnologies Details 2.12.2 FUJIFILM Diosynth Biotechnologies Major Business 2.12.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.12.4 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.12.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans 2.13 Biovian 2.13.1 Biovian Details 2.13.2 Biovian Major Business 2.13.3 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.13.4 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.13.5 Biovian Recent Developments and Future Plans 2.14 Miltenyi Bioindustry 2.14.1 Miltenyi Bioindustry Details 2.14.2 Miltenyi Bioindustry Major Business 2.14.3 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.14.4 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.14.5 Miltenyi Bioindustry Recent Developments and Future Plans 2.15 Aldevron 2.15.1 Aldevron Details 2.15.2 Aldevron Major Business 2.15.3 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.15.4 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.15.5 Aldevron Recent Developments and Future Plans 2.16 Takara Bio 2.16.1 Takara Bio Details 2.16.2 Takara Bio Major Business 2.16.3 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.16.4 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.16.5 Takara Bio Recent Developments and Future Plans 2.17 Yposkesi 2.17.1 Yposkesi Details 2.17.2 Yposkesi Major Business 2.17.3 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.17.4 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.17.5 Yposkesi Recent Developments and Future Plans 2.18 Genezen 2.18.1 Genezen Details 2.18.2 Genezen Major Business 2.18.3 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.18.4 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.18.5 Genezen Recent Developments and Future Plans 2.19 Exthera 2.19.1 Exthera Details 2.19.2 Exthera Major Business 2.19.3 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.19.4 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.19.5 Exthera Recent Developments and Future Plans 2.20 GenScript ProBio 2.20.1 GenScript ProBio Details 2.20.2 GenScript ProBio Major Business 2.20.3 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.20.4 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.20.5 GenScript ProBio Recent Developments and Future Plans 2.21 EurekaBio 2.21.1 EurekaBio Details 2.21.2 EurekaBio Major Business 2.21.3 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.21.4 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.21.5 EurekaBio Recent Developments and Future Plans 2.22 Obio Technology 2.22.1 Obio Technology Details 2.22.2 Obio Technology Major Business 2.22.3 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.22.4 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.22.5 Obio Technology Recent Developments and Future Plans 2.23 GeneSail Biotech 2.23.1 GeneSail Biotech Details 2.23.2 GeneSail Biotech Major Business 2.23.3 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.23.4 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.23.5 GeneSail Biotech Recent Developments and Future Plans 2.24 VectorBuilder 2.24.1 VectorBuilder Details 2.24.2 VectorBuilder Major Business 2.24.3 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.24.4 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.24.5 VectorBuilder Recent Developments and Future Plans 2.25 WuXi ATU 2.25.1 WuXi ATU Details 2.25.2 WuXi ATU Major Business 2.25.3 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.25.4 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.25.5 WuXi ATU Recent Developments and Future Plans 2.26 Ubrigene 2.26.1 Ubrigene Details 2.26.2 Ubrigene Major Business 2.26.3 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.26.4 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.26.5 Ubrigene Recent Developments and Future Plans 2.27 Porton Biologics 2.27.1 Porton Biologics Details 2.27.2 Porton Biologics Major Business 2.27.3 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.27.4 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.27.5 Porton Biologics Recent Developments and Future Plans 2.28 Pharmaron 2.28.1 Pharmaron Details 2.28.2 Pharmaron Major Business 2.28.3 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.28.4 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.28.5 Pharmaron Recent Developments and Future Plans 2.29 PackGene Biotechnology 2.29.1 PackGene Biotechnology Details 2.29.2 PackGene Biotechnology Major Business 2.29.3 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions 2.29.4 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, Gross Margin and Market Share (2021-2026) 2.29.5 PackGene Biotechnology Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue and Share by Players (2021-2026) 3.2 Market Share Analysis (2025) 3.2.1 Market Share of Adeno-Associated Virus (AAV) Vector Production CDMO by Company Revenue 3.2.2 Top 3 Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share in 2025 3.2.3 Top 6 Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share in 2025 3.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market: Overall Company Footprint Analysis 3.3.1 Adeno-Associated Virus (AAV) Vector Production CDMO Market: Region Footprint 3.3.2 Adeno-Associated Virus (AAV) Vector Production CDMO Market: Company Product Type Footprint 3.3.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market: Company Product Application Footprint 3.4 New Market Entrants and Barriers to Market Entry 3.5 Mergers, Acquisition, Agreements, and Collaborations 4 Market Size Segment by Type 4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value and Market Share by Type (2021-2026) 4.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Forecast by Type (2027-2032) 5 Market Size Segment by Application 5.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2026) 5.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Forecast by Application (2027-2032) 6 North America 6.1 North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2032) 6.2 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (2021-2032) 6.3 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country 6.3.1 North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2032) 6.3.2 United States Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 6.3.3 Canada Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 6.3.4 Mexico Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 7 Europe 7.1 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2032) 7.2 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2032) 7.3 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country 7.3.1 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2032) 7.3.2 Germany Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 7.3.3 France Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 7.3.4 United Kingdom Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 7.3.5 Russia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 7.3.6 Italy Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8 Asia-Pacific 8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2032) 8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2032) 8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region 8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Region (2021-2032) 8.3.2 China Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8.3.3 Japan Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8.3.4 South Korea Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8.3.5 India Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8.3.6 Southeast Asia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 8.3.7 Australia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 9 South America 9.1 South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2032) 9.2 South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2032) 9.3 South America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country 9.3.1 South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2032) 9.3.2 Brazil Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 9.3.3 Argentina Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 10 Middle East & Africa 10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2032) 10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2032) 10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country 10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2032) 10.3.2 Turkey Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 10.3.3 Saudi Arabia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 10.3.4 UAE Adeno-Associated Virus (AAV) Vector Production CDMO Market Size and Forecast (2021-2032) 11 Market Dynamics 11.1 Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers 11.2 Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints 11.3 Adeno-Associated Virus (AAV) Vector Production CDMO Trends Analysis 11.4 Porters Five Forces Analysis 11.4.1 Threat of New Entrants 11.4.2 Bargaining Power of Suppliers 11.4.3 Bargaining Power of Buyers 11.4.4 Threat of Substitutes 11.4.5 Competitive Rivalry 12 Industry Chain Analysis 12.1 Adeno-Associated Virus (AAV) Vector Production CDMO Industry Chain 12.2 Adeno-Associated Virus (AAV) Vector Production CDMO Upstream Analysis 12.3 Adeno-Associated Virus (AAV) Vector Production CDMO Midstream Analysis 12.4 Adeno-Associated Virus (AAV) Vector Production CDMO Downstream Analysis 13 Research Findings and Conclusion 14 Appendix 14.1 Methodology 14.2 Research Process and Data Source 14.3 Disclaimer
圖表清單 List of Tables & Figures
List of Tables Table 1. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032 Table 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032 Table 3. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Region (2021-2026) & (USD Million) Table 4. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Region (2027-2032) & (USD Million) Table 5. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors Table 6. Thermo Fisher Scientific Major Business Table 7. Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 8. Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 9. Thermo Fisher Scientific Recent Developments and Future Plans Table 10. Lonza Company Information, Head Office, and Major Competitors Table 11. Lonza Major Business Table 12. Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 13. Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 14. Lonza Recent Developments and Future Plans Table 15. Catalent Company Information, Head Office, and Major Competitors Table 16. Catalent Major Business Table 17. Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 18. Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 19. Charles River Company Information, Head Office, and Major Competitors Table 20. Charles River Major Business Table 21. Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 22. Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 23. Charles River Recent Developments and Future Plans Table 24. Merck Company Information, Head Office, and Major Competitors Table 25. Merck Major Business Table 26. Merck Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 27. Merck Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 28. Merck Recent Developments and Future Plans Table 29. SK pharmteco Company Information, Head Office, and Major Competitors Table 30. SK pharmteco Major Business Table 31. SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 32. SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 33. SK pharmteco Recent Developments and Future Plans Table 34. Oxford Biomedica Company Information, Head Office, and Major Competitors Table 35. Oxford Biomedica Major Business Table 36. Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 37. Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 38. Oxford Biomedica Recent Developments and Future Plans Table 39. AGC Biologics（MolMed） Company Information, Head Office, and Major Competitors Table 40. AGC Biologics（MolMed） Major Business Table 41. AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 42. AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 43. AGC Biologics（MolMed） Recent Developments and Future Plans Table 44. Gene Universal Company Information, Head Office, and Major Competitors Table 45. Gene Universal Major Business Table 46. Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 47. Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 48. Gene Universal Recent Developments and Future Plans Table 49. Polyplus (Sartorius) Company Information, Head Office, and Major Competitors Table 50. Polyplus (Sartorius) Major Business Table 51. Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 52. Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 53. Polyplus (Sartorius) Recent Developments and Future Plans Table 54. CCRM Company Information, Head Office, and Major Competitors Table 55. CCRM Major Business Table 56. CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 57. CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 58. CCRM Recent Developments and Future Plans Table 59. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors Table 60. FUJIFILM Diosynth Biotechnologies Major Business Table 61. FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 62. FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 63. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans Table 64. Biovian Company Information, Head Office, and Major Competitors Table 65. Biovian Major Business Table 66. Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 67. Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 68. Biovian Recent Developments and Future Plans Table 69. Miltenyi Bioindustry Company Information, Head Office, and Major Competitors Table 70. Miltenyi Bioindustry Major Business Table 71. Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 72. Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 73. Miltenyi Bioindustry Recent Developments and Future Plans Table 74. Aldevron Company Information, Head Office, and Major Competitors Table 75. Aldevron Major Business Table 76. Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 77. Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 78. Aldevron Recent Developments and Future Plans Table 79. Takara Bio Company Information, Head Office, and Major Competitors Table 80. Takara Bio Major Business Table 81. Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 82. Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 83. Takara Bio Recent Developments and Future Plans Table 84. Yposkesi Company Information, Head Office, and Major Competitors Table 85. Yposkesi Major Business Table 86. Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 87. Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 88. Yposkesi Recent Developments and Future Plans Table 89. Genezen Company Information, Head Office, and Major Competitors Table 90. Genezen Major Business Table 91. Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 92. Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 93. Genezen Recent Developments and Future Plans Table 94. Exthera Company Information, Head Office, and Major Competitors Table 95. Exthera Major Business Table 96. Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 97. Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 98. Exthera Recent Developments and Future Plans Table 99. GenScript ProBio Company Information, Head Office, and Major Competitors Table 100. GenScript ProBio Major Business Table 101. GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 102. GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 103. GenScript ProBio Recent Developments and Future Plans Table 104. EurekaBio Company Information, Head Office, and Major Competitors Table 105. EurekaBio Major Business Table 106. EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 107. EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 108. EurekaBio Recent Developments and Future Plans Table 109. Obio Technology Company Information, Head Office, and Major Competitors Table 110. Obio Technology Major Business Table 111. Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 112. Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 113. Obio Technology Recent Developments and Future Plans Table 114. GeneSail Biotech Company Information, Head Office, and Major Competitors Table 115. GeneSail Biotech Major Business Table 116. GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 117. GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 118. GeneSail Biotech Recent Developments and Future Plans Table 119. VectorBuilder Company Information, Head Office, and Major Competitors Table 120. VectorBuilder Major Business Table 121. VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 122. VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 123. VectorBuilder Recent Developments and Future Plans Table 124. WuXi ATU Company Information, Head Office, and Major Competitors Table 125. WuXi ATU Major Business Table 126. WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 127. WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 128. WuXi ATU Recent Developments and Future Plans Table 129. Ubrigene Company Information, Head Office, and Major Competitors Table 130. Ubrigene Major Business Table 131. Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 132. Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 133. Ubrigene Recent Developments and Future Plans Table 134. Porton Biologics Company Information, Head Office, and Major Competitors Table 135. Porton Biologics Major Business Table 136. Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 137. Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 138. Porton Biologics Recent Developments and Future Plans Table 139. Pharmaron Company Information, Head Office, and Major Competitors Table 140. Pharmaron Major Business Table 141. Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 142. Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 143. Pharmaron Recent Developments and Future Plans Table 144. PackGene Biotechnology Company Information, Head Office, and Major Competitors Table 145. PackGene Biotechnology Major Business Table 146. PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Product and Solutions Table 147. PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026) Table 148. PackGene Biotechnology Recent Developments and Future Plans Table 149. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (USD Million) by Players (2021-2026) Table 150. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Share by Players (2021-2026) Table 151. Breakdown of Adeno-Associated Virus (AAV) Vector Production CDMO by Company Type (Tier 1, Tier 2, and Tier 3) Table 152. Market Position of Players in Adeno-Associated Virus (AAV) Vector Production CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025 Table 153. Head Office of Key Adeno-Associated Virus (AAV) Vector Production CDMO Players Table 154. Adeno-Associated Virus (AAV) Vector Production CDMO Market: Company Product Type Footprint Table 155. Adeno-Associated Virus (AAV) Vector Production CDMO Market: Company Product Application Footprint Table 156. Adeno-Associated Virus (AAV) Vector Production CDMO New Market Entrants and Barriers to Market Entry Table 157. Adeno-Associated Virus (AAV) Vector Production CDMO Mergers, Acquisition, Agreements, and Collaborations Table 158. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (USD Million) by Type (2021-2026) Table 159. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Share by Type (2021-2026) Table 160. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Forecast by Type (2027-2032) Table 161. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) Table 162. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Forecast by Application (2027-2032) Table 163. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2026) & (USD Million) Table 164. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2027-2032) & (USD Million) Table 165. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) & (USD Million) Table 166. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2027-2032) & (USD Million) Table 167. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2026) & (USD Million) Table 168. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2027-2032) & (USD Million) Table 169. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2026) & (USD Million) Table 170. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2027-2032) & (USD Million) Table 171. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) & (USD Million) Table 172. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2027-2032) & (USD Million) Table 173. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2026) & (USD Million) Table 174. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2027-2032) & (USD Million) Table 175. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2026) & (USD Million) Table 176. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2027-2032) & (USD Million) Table 177. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) & (USD Million) Table 178. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2027-2032) & (USD Million) Table 179. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Region (2021-2026) & (USD Million) Table 180. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Region (2027-2032) & (USD Million) Table 181. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2026) & (USD Million) Table 182. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2027-2032) & (USD Million) Table 183. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) & (USD Million) Table 184. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2027-2032) & (USD Million) Table 185. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2026) & (USD Million) Table 186. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2027-2032) & (USD Million) Table 187. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2021-2026) & (USD Million) Table 188. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type (2027-2032) & (USD Million) Table 189. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2021-2026) & (USD Million) Table 190. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application (2027-2032) & (USD Million) Table 191. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2021-2026) & (USD Million) Table 192. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Country (2027-2032) & (USD Million) Table 193. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO Upstream (Raw Materials) Table 194. Global Adeno-Associated Virus (AAV) Vector Production CDMO Typical Customers List of Figures Figure 1. Adeno-Associated Virus (AAV) Vector Production CDMO Picture Figure 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032 Figure 3. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type in 2025 Figure 4. Adherent Culture Figure 5. Suspension Culture Figure 6. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032 Figure 7. Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application in 2025 Figure 8. Vaccine Development Picture Figure 9. Gene Therapy Picture Figure 10. Academic Scientific Research Institution Picture Figure 11. Others Picture Figure 12. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value, (USD Million): 2021 & 2025 & 2032 Figure 13. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value and Forecast (2021-2032) & (USD Million) Figure 14. Global Market Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032) Figure 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Region (2021-2032) Figure 16. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Region in 2025 Figure 17. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 18. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 19. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 20. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 21. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 22. Company Three Recent Developments and Future Plans Figure 23. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Share by Players in 2025 Figure 24. Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025 Figure 25. Market Share of Adeno-Associated Virus (AAV) Vector Production CDMO by Player Revenue in 2025 Figure 26. Top 3 Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share in 2025 Figure 27. Top 6 Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share in 2025 Figure 28. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Share by Type (2021-2026) Figure 29. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share Forecast by Type (2027-2032) Figure 30. Global Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Share by Application (2021-2026) Figure 31. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share Forecast by Application (2027-2032) Figure 32. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type (2021-2032) Figure 33. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2032) Figure 34. North America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Country (2021-2032) Figure 35. United States Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 36. Canada Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 37. Mexico Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 38. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type (2021-2032) Figure 39. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2032) Figure 40. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Country (2021-2032) Figure 41. Germany Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 42. France Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 43. United Kingdom Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 44. Russia Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 45. Italy Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 46. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type (2021-2032) Figure 47. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2032) Figure 48. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Region (2021-2032) Figure 49. China Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 50. Japan Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 51. South Korea Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 52. India Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 53. Southeast Asia Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 54. Australia Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 55. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type (2021-2032) Figure 56. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2032) Figure 57. South America Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Country (2021-2032) Figure 58. Brazil Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 59. Argentina Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 60. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Type (2021-2032) Figure 61. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Application (2021-2032) Figure 62. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value Market Share by Country (2021-2032) Figure 63. Turkey Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 64. Saudi Arabia Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 65. UAE Adeno-Associated Virus (AAV) Vector Production CDMO Consumption Value (2021-2032) & (USD Million) Figure 66. Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers Figure 67. Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints Figure 68. Adeno-Associated Virus (AAV) Vector Production CDMO Market Trends Figure 69. Porters Five Forces Analysis Figure 70. Adeno-Associated Virus (AAV) Vector Production CDMO Industrial Chain Figure 71. Methodology Figure 72. Research Process and Data Source

提及公司

Thermo Fisher ScientificLonzaCatalentCharles RiverMerckSK pharmtecoOxford BiomedicaAGC Biologics（MolMed）Gene UniversalPolyplus (Sartorius)CCRMFUJIFILM Diosynth BiotechnologiesBiovianMiltenyi BioindustryAldevronTakara BioYposkesiGenezenExtheraGenScript ProBioEurekaBioObio TechnologyGeneSail BiotechVectorBuilderWuXi ATUUbrigenePorton BiologicsPharmaronPackGene Biotechnology

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Global Info Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們